SBP solbec pharmaceuticals limited

solbec signs with hybridon

  1. 5,996 Posts.
    lightbulb Created with Sketch. 162
    Hybridon is an industry leader in synthetic DNA , second generation antisense and its products are being used by several cos in current clinical trials . Eg Aegeras XIAP trial in the UK .
    Cheers
    'SOLBEC AGREEMENT WITH HYBRIDON INC.
    Summary:
    • Solbec has signed a material transfer agreement with Hybridon Inc. that covers the supply
    of a synthetic TLR9 agonist from Hybridon for use in further pre-clinical evaluation.
    Perth, 20 December 2004: Solbec Pharmaceuticals Ltd (ASX:SBP) announced today that it has
    signed a Material Transfer Agreement with Hybridon Inc. of Cambridge, Massachusetts. The
    agreement gives Solbec access to one of Hybridon’s Immunomodulatory Oligonucleotide
    (IMO™) agonists of Toll-like receptor 9 (TLR9) that will be used in combination with Solbec’s
    Coramsine™ for pre-clinical evaluation.
    The forthcoming study will be carried out by the Tumour Immunology Group at the University of
    Western Australia and will evaluate combinational immunotherapy in the treatment of malignant
    mesothelioma and melanoma.
    The evaluation is intended to confirm and extend the findings of a study, announced to the ASX
    on 23rd November 2004, and is an essential step in preparing for an initial clinical trial of
    combination therapy in patients.
    Further information:
    About Solbec
    Solbec Pharmaceuticals Ltd identifies naturally-occurring compounds with potential in the development of
    better therapies for debilitating conditions and life-threatening diseases. The company is currently
    progressing its key project, Coramsine™, through Phase I/IIA clinical trials for the treatment of
    mesothelioma and malignant melanoma, and as a topical treatment for psoriasis. Solbec's two proprietary
    ingredients in Coramsine™ were isolated from the fruit of a weed known as the Devil’s Apple (Solanum
    linnaeanum). They show activity against some cancers and cause potentially therapeutic changes to the
    immune system. In addition to human health, Coramsine™ has potential application in the areas of animal
    health and diagnostics. Solbec’s business strategy is to partner or out-license Coramsine™ for the final
    stages of pre-commercial development and marketing.
    About Hybridon Inc.
    Hybridon, Inc. is engaged in the discovery, development, and commercialization of novel therapeutics
    based on synthetic DNA for the treatment of cancer, asthma/allergies, and infectious diseases. Hybridon’s
    drug candidates are designed to modulate immune responses through Toll-like receptor 9 and antisense and
    are based on innovative DNA chemistries developed at Hybridon.
    The Agreement
    The Material Transfer Agreement has been negotiated under standard commercial terms to provide access
    to Hybridon IMO™ materials for the purposes of pre-clinical evaluation of combination therapy with
    Coramsine.
    Solbec supports the principles contained in the working draft ASX & Ausbiotech Code of Best
    Practice for Reporting by Biotechnology, Medical Device and other Life Sciences Companies.
    Information contained in this communication is in accord with the Code.
    For further information, please contact
    Stephen Carter
    Managing Director
    Solbec Pharmaceuticals Ltd
    Australia
    Phone +61 (08) 944 67555
    www.solbec.com.au
    Tim Sullivan, Ph.D.
    V.P Development Programs
    Hybridon, Inc.
    USA
    Telephone: +1 (617) 679-5500
    www.hybridon.com
    Media:
    Rebecca Christie
    Phone: +61 (02) 9237 2800 / 0417 382 391
    [email protected]
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.